Jul. 21 at 3:57 PM
$CRBP BUT there actually seems to be an answer in the form of compound JD5037 / CRB-4001. This is the predecessor of the current drug CRB-913 which the company phased out and concentrated on CRB-913. But before doing that there was a lot of preclinical work done with it and as it happens it was almost entirely peripherally restricted. Even more so compared to CRB-913 so it serves as a nice test of whether peripheral exposure limits the efficacy of this MOA. And according to the preclinical data it doesn't: "We report that a peripherally restricted CB1R inverse agonist, JD5037, is equieffective with its brain-penetrant parent compound in decreasing daily food intake, body weight, and adiposity in DIO mice".
